Q-omics provides the consensus-scored ETFRF1 profile across patient tissues and cancer cell-line models. ETFRF1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ETFRF1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, ETFRF1 RNA expression shows 19,583 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRP, and UVM as cancer lineages where ETFRF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETFRF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETFRF1 survival associations across molecular data types. ETFRF1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETFRF1 RNA expression–survival associations across cancer types. High ETFRF1 expression shows unfavorable associations in SCLC and UVM, but favorable associations in MESO, LAML, OV and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for ETFRF1 RNA expression.
This table summarizes ETFRF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ETFRF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETFRF1 shows lower tumor expression in KIRP, KIRC, THCA, LUSC, LUAD and KICH. The KIRP box plot shows higher ETFRF1 RNA expression in normal versus tumor tissue (log2 FC = −0.796, t-test p < 0.001).
This table shows molecular features associated with ETFRF1 in patient tissues and cancer cell lines. In patient samples, ETFRF1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ETFRF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
